key: cord-0720692-wtot7hsj
authors: Das, Sanchita; Frank, Karen M.
title: Strategies for Scaling Up SARS-CoV-2 Molecular Testing Capacity
date: 2022-03-08
journal: Clin Lab Med
DOI: 10.1016/j.cll.2022.02.006
sha: 63e088897aa92a1c11d5a5e9eaa645e52c4c4ba0
doc_id: 720692
cord_uid: wtot7hsj

Scaling up SARS-CoV-2 testing during the COVID-19 pandemic was critical to maintain clinical operations and an open society. Pooled testing and automation were two critical strategies used by laboratories to meet unprecedented demand.Here, we review these and other cutting edge strategies that sought to expand SARS-CoV-2 testing capacity while maintaining high individual test performance.

Scaling up SARS-CoV-2 testing during the COVID-19 pandemic was critical to maintain clinical 25 operations and an open society. Pooled testing and automation were two critical strategies used by 26 laboratories to meet unprecedented demand.Here, we review these and other cutting edge strategies 27 that sought to expand SARS-CoV-2 testing capacity while maintaining high individual test performance. 28

More than 413 million people have been infected with the Severe Acute Respiratory Syndrome 31

Coronavirus-2 (SARS-CoV-2) resulting in more than 5.8 million deaths worldwide. 1 Testing for the virus 32 at high volumes has been essential in the battle against the pandemic, yet there continues to be huge 33 variation in the ability of different countries to keep up with their testing needs. The number of tests 34 per confirmed case has varied widely as has the total cumulative cases per country. In March 2020, the 35 United States was averaging 21 tests per confirmed case whereas Taiwan was performing 211 tests per 36 confirmed case. Nearly one year later at the beginning of February 2021, the United States was still 37 performing just 12 tests per confirmed case compared to Australia, with 451 tests per confirmed case. 38 Importantly, the overall volume of testing in the United States was quite large, with more than 457 39 million SARS-CoV-2 tests performed by mid-June 2021. 2 Target populations for testing were highly 40 diverse and included patients being admitted to a hospital or being evaluated in a clinic, asymptomatic 41 individuals at work, or students in educational institutions. In this review, we will address the 42 approaches used to increase the capacity of molecular testing for viral RNA, as this remains an 43 important and challenging problem and the lessons learned in the response to SARS-CoV-2 are 44 applicable to future infectious disease pandemics. 45 46 Strategies used to scale up testing capacity 47

The optimal size of a pool is dependent on the prevalence of the disease, as well as the pooling 144 algorithm. As the number of positive pools increases with rising prevalence, the number of tests 145 performed approaches or exceeds that of standard non-pooling methods, thereby negating the savings 146 that would have been realized through more efficient use of reagents. Thus, while the theoretical 147 benefits of pooling have been demonstrated up to a positivity rate of 30%, at such high levels the pool 148 size would need to be exceedingly small to prevent every pool from testing positive and requiring 149 deconvolution. Pool sizes of ten are optimal over a broader range of prevalence and most studies 150 recommend pooling only if the prevalence is less than 10%. 17, 18 Commonly suggested pool sizes range 151 from four to ten, though some studies advocate for 32 to 64 samples per pool (Table 1) . 7, 19-27 152 The largest real-world study evaluating the performance of a pooled testing strategy comes from Barak 153 based on the location of testing (nursing homes, colleges, healthcare settings), resulted in a 76% 158 reduction in the number of PCR reactions, which exceeded the predicted performance of their strategy. 159

The authors note the ability to adjust pool size was facilitated by their use of automated liquid 160 handers. 28 A study by Petrovan et al. reported efficient detection with pools of up to 80 specimens, but 161 the study validated their protocol using only specimens with high viral loads, therefore conclusions 162 cannot be generalized to settings where it is expected that a significant proportion of specimens will 163 have lower viral loads. 29 

Sensitivity of pooled testing 166 J o u r n a l P r e -p r o o f A primary concern with combining multiple specimens into a pool is that it will dilute the signal of 167 individual tests, resulting in the missed detection of low viral load specimens. However, nucleic acid 168 amplification tests for viral RNA are highly sensitive, with a limit of detection as low as five copies of 169 virus per reaction. This degree of sensitivity is the basis for why pooling has been immensely successful 170 for HIV and hepatitis as there is only a minor loss of sensitivity. With SARS-CoV-2, the realization that 171 specimens with low viral loads are often (though not always) associated with a lower transmission risk 172 paved the way for pooling methods to be accepted by laboratory, hospital and public health leadership. 173

Multiple studies have now demonstrated that the slight loss of sensitivity from pooling samplings does 174 not affect the detection of virus from individual samples when they contain RNA levels that correspond 175 to transmissible disease. In most studies this equates to Ct values below 35. 30-32 Importantly, a key 176 decision for an institution is setting the upper bound for Ct value that must be detected in their assay. 177

For example, do specimens with viral loads corresponding to a Ct value of 38 need to be detected, or 178 should only specimens with a Ct value of 34 and lower be considered essential for identification? 179

Ultimately, determining an acceptable loss of sensitivity is a subjective determination of the highest Ct 180 value present in the individuals most likely to spread disease, and must be informed by careful 181 epidemiologic studies that are specific to the set of SARS-CoV-2 variants in current circulation. 33 182

The key parameter influencing sensitivity is pool size. Wang et al. examined a lab-developed test and 183

Panther assays with pools of four reporting a sensitivity of 83-100% and with pools of eight reporting a 184 sensitivity of 72-83%. All false negatives had a Ct value greater than 34. 34 Abdalhamid et al. reported 185 that pools of five specimens dropped the highest detectable Ct value of an individual specimen by 0 to 5 186 cycles, though it also reduced the number of tests performed by 69%. 35 Griesemer et al. of 93%, 89% and 85% for saliva pool sizes of five, ten, and twenty, respectively. 33 A study by Mahmoud 190 When properly calibrated to prevalence, pooled testing strategies result in significant savings. However, 205 this comes at the cost of increased pre-and post-analytic complexity. Specimen handling becomes more 206 challenging as the pools must be made by an instrument or a technologist. Uncapping and recapping 207 tubes can become a limiting factor for some automated workflows. Furthermore, the larger the pool 208 size, the higher the risk of a specimen mix-up at the time of deconvolution. 209 A limitation of pooling is that it removes the ability to assess for individual sampling adequacy through a 210 positive internal control, such as the human RNAse P gene. However, our experience has been that the 211 rate of inadequate samples was extremely low for nasopharygeal, mid-turbinate, and saliva collections, 212 therefore this is not likely to be a major drawback. It should be noted that pooling does not reduce the 213 workload for reporting and billing, and instead has increased the work for the information technology 214 staff who must create new data management algorithms for result reporting. 40 CoV-2 molecular testing. Lessons learned from the current pandemic will serve to inform laboratories 219 that may need rapid scale-up of testing in the future. 220

Highly sensitive RT-PCR testing and contact tracing has been the cornerstone of containment strategies 223 during the pandemic, but is predicated on the ability to return accurate results as fast as possible. 224

Mathematical modelling showed that testing delays of more than three days significantly reduces the 225 prevention of transmission by contact tracing. 41 Recognizing the need for expanded capacity of rapid 226 testing, initiatives such as the NIH RADx were developed early in the pandemic to speed development of 227 new tests. 42 These and other studies recognized several challenges that would need to be overcome 228 before large scale testing could be instituted. 229

Challenges to implementation of RT-PCR based large-scale testing include the availability of high-230 throughput assays and platforms, adequate access to sufficient reagents, laboratory infrastructure and 231 the ability for laboratories to develop and validate new assays, the availability of trained personnel and 232 the costs of implementing high capacity population-based testing strategies. [43] [44] [45] We consider several 233 strategies to overcome these challenges in the following sections. 234

One of the simplest means of increasing testing capacity is to increase use of automated RNA extraction 238 methods. Indeed, global shortages and bottlenecks in production of extraction reagents prompted an 239 assortment of studies that investigated alternate extraction procedures or direct PCR amplification on 240 specimens. 20 showed acceptable sensitivity and specificity in SARS-CoV-2 samples with Ct values of <33. 49 Use of 262 detergents and guanidinium isothiocyanate with chloroform for direct sample preparation showed 263 variable sensitivity. Of note, some of these studies demonstrated a loss of sensitivity when detergents or 264 other extraction reagents or heat inactivation methods were used in direct sample preparation in RT-265 PCR. [50] [51] [52] Caution and proper biosafety precautions should also be used when using these non-extraction 266 sample preparations to determine the level of viral inactivation. 49, 53 267 Combining methods to reduce extraction steps and multiplexing several probes in a single 268 reaction is also an effective way of increasing capacity. An additional advantage of multiplexed assays is 269 panel testing that includes other respiratory viral targets. This would significantly increase testing (Table 2) , but there are differences in the functionality of these 295 platforms, including throughput per 8-hour work shift, technician hands-on time, and random-access 296 capability. Many clinical laboratories use multiple platforms simultaneously to efficiently increase 297 testing capacity while maintaining flexibility to satisfy a wide range of clinical needs. Table 3 summarizes 298 the factors that may be considered by the laboratory before implementing these relatively expensive 299 platforms. 300

Diversification of technologies can also aid in scale up of testing, especially given the concerns 303 with reagent availability and supply chain issues. Several new technologies have been developed during 304 the pandemic that can be implemented in large-scale testing. 305 CRISPR and associated Cas protein-based diagnostics are powerful methods for nucleic acid 306 detection using cleavage activity. These are typically used in conjunction with RT-LAMP and other 307 isothermal methods. The assays SHERLOCK AND DETECTR have been validated on clinical specimens and 308 are based on cleavage of reporter RNA molecules by the Cas12/13 enzymes. 57 They are available in 309 lateral flow and fluorescent based readouts and have also been adapted for direct testing of specimens. 310

Further modification of the RNA extraction step by using magnetic beads in conjunction with CRISPR 311 based assay has been used to expedite detection of SARS-CoV-2 RNA in a "one-pot" test. 58-60 A platform 312 for rapidly scalable diagnostic testing with multiplexing capability has been described by Ackerman et al. 313 in the CARMEN-Cas13 assay design. 61 This immensely scalable platform is based on CRISPR-Cas13 314 detection system and applied in a combinatorial plate based format to increase throughput and 315 multiplexing capability. 316

Nanotechnology is another technology that could reduce reagent cost. Use of magnetic 317 nanoparticles for RNA extraction can significantly scale up diagnostic testing and has been advocated for 318 areas with limited resources. 62 The small size and photostability of quantum dots and gold nanoparticles 319 have been utilized in a colorimetric assay to detect SARS-CoV-2 nucloecapsid gene RNA. Another 320 example is a clinical diagnostic biosensor molecule using gold nano-islands, which can precisely detect 321 selected SARS-CoV-2 sequences in a multigene mixture with low false positive rates. 63, 64 Finally, 322 biosensors using graphene-gold nanoparticle platform can generate an electric readout that was found 323 to be highly sensitive and accurate with rapid turn-around time. 65 324 Isothermal amplification techniques such as reverse transcription loop-mediated isothermal 325 amplification (RT-LAMP) have been investigated to ramp up testing as they do not require thermal 326 amplification and therefore the need to transport specimens to a centralized laboratory. They are also 327 amenable to testing crude samples as they are relatively agnostic to PCR inhibitors. Use of multiple 328 primers increases the versatility of these assays in multiplexed reactions. The major disadvantage of the 329 isothermal techniques is the lower sensitivity and specificity when compared to RT-PCR and the 330 requirement for significant optimization for performance comparable to conventional RT-PCR. Several 331 iterations of these assays have been developed in the form of lateral flow or biosensor-based platforms 332 for use in large scale testing at entry points, after addressing the performance characteristics. 66 are not limited to: regulatory compliance, complexity of the assays, and adaptability to the CLIA certified 339 laboratory. Finally, the biggest bottleneck is finding commercial partners such that the reagent and 340 consumable supply chain can be maintained as long as enhanced testing capacity is required. 341 342

The need to understand the route of transmission, phylogeny and molecular evolution of the 344 virus was appreciated early in the pandemic. The emergence of more transmissible variants of SARS-345

CoV-2 or those that evade immunity induced by vaccines have prompted the development of novel 346 therapeutics. The changing landscape of viral variants underscore the need to monitor their evolution in 347 real-time. 69 Global surveillance efforts (such as COGUK) 70 and sharing of genome sequences in publicly 348 available databases (GISAID) 71 has made an immense impact in efforts to understand the evolution and 349 spread of the viral mutants as well as in studying the immune response to vaccines. 72 Several 350 commercial assays based on NGS have been adapted to high-throughput formats. These platforms can 351 provide comprehensive information about viral genomes for thousands of individuals in a single run. 73, 74 352 Another important role played by NGS is the monitoring and surveillance of environmental samples, 353 such as wastewater for SARS-CoV-2. 75 Levels of viral RNA in these samples have been shown to rise and 354 fall ahead of case counts making their monitoring useful for early warning systems, including for the 355 detection of variants of concern. 76 Rapid multiplexed RT-PCR based assays that detect mutations 356 defining variants of concern have been described for both surveillance and screening. 77-79 357

As newer technologies and innovative platforms are introduced to laboratories worldwide, 359 strategies must be developed to expeditiously remove the bottlenecks of standardization and validation 360 globally. Maintenance of quality control of reagents will be important in deployment of assays. Industry 361 partnership and collaboration with local regulatory authorities will need to be planned. 80 Most 362 importantly, continuous maintenance of the global supply chain is needed to sustain testing capacity. 363

Another important limitation is that the performance of RT-PCR and other molecular assays have 364 been variable based on the specimen source. Early in the pandemic, lower respiratory swab specimens 365 were reported to be more sensitive in detecting low viral copy numbers than upper respiratory tract 366 specimens. 35 Alternate specimen types such as saliva and oropharyngeal swabs were extremely useful in 367 diagnostic and surveillance testing while stool, urine and blood were not deemed to have sufficient 368 sensitivity to be of use. This variation of detectable RNA quantity in specimen sources will continue to 369 affect the sensitivity and specificity of assays that are being developed. Carefully done studies 370 comparing test performance by body site of collection using standardized gold standards are essential 371 for informing testing algorithms and will become increasingly important as the virus evolves to have new 372 tissue tropism. In addition, RT-PCR assays do not provide essential information regarding viability of the 373 virus. 374

As with many molecular assays for RNA viruses, continuous monitoring of the performance of 375 primers and probes needs to be performed as mutations accrue due to the natural evolution of the virus 376 in response to immune selective pressures and other forces. Significant mutations in the primer/probe 377 binding sites can alter the performance of an assay thus affecting diagnosis and control efforts. FDA 378 monitors SARS-CoV-2 mutations for possible impact on assay performance, 81 but clinical labs are often 379 the first place that changes in analytic performance are noted due to their close involvement with 380 clinicians treating patients with COVID-19. The need to scale up genomic surveillance to detect viral 381 mutants will continue to remain a challenge in the near future. 82 A summary of the challenges of high 382 capacity testing is shown in Figure 2 . 383

Clinical laboratories have stepped up to the unprecedented challenges brought on by the 385 COVID-19 pandemic. Although sufficient testing was not available during the initial weeks of the 386 pandemic, multiple strategies were successfully used to address the challenge of extremely high 387 capacity testing with reliable results. Although many approaches to pooling were proposed, the simple 388 Dorfman algorithm of combining four to ten original specimens prior to extraction is the most frequently 389 used. Traditional RT-PCR platforms evolved from low-throughput lab developed assays to emergency-390 use authorized commercial assays on high-throughput platforms. However, the diversification of 391 platforms only partially alleviated the supply shortages which persisted for many months. These 392 Table 3 Factors to consider prior to acquisition of automated platforms for high-throughput assays during a time of crisis

Is this the right assay for this disease?

• Clinical condition being tested • Specimen types or matrix that will be tested • Instrument turn-around time Clinical and analytic performance characteristics of assay:

• Sensitivity • Specificity • Lower limit of detection • Positive and negative predictive value Is this the appropriate instrument for this test?

• Throughput of instrument (number of tests per 8-hour shift) • Hands-on time required before specimen is loaded on instrument • Availability of reagents, compatibility with commercial reagents

• Batch tested versus random access • Available staffing • Backup plans to mitigate risks for reagent or supply shortages Is this the appropriate instrument for my laboratory?

• Cost of the instrument and cost per assay • Price of maintenance and repairs • Compatibility with existing testing protocols used in the laboratory • Adaptability to future tests that may be introduced to the laboratory • Instrument footprint

• 5-year return on investment • Service contract costs • Downtime associated with maintenance • Capability to transition laboratory developed assays to the automated platform • Assessment of assays that are in development for this instrument and whether they fit into with the future plan of the laboratory • Available laboratory space • Need for current or future construction 

An interactive web-based dashboard to track COVID-19 in real time

The detection of defective members of large populations

A robust pooled testing approach to expand COVID-19 screening capacity

Pooling of samples to optimize SARS-CoV-2 diagnosis by RT-qPCR: comparative analysis of two protocols

Concentrating Pooled COVID-19 Patient Lysates to Improve Reverse Transcription Quantitative PCR Sensitivity and Efficiency

Sample pooling as a strategy for community monitoring for SARS-CoV-2

Swab pooling: A new method for large-scale RT-qPCR screening of SARS-CoV-2 avoiding sample dilution

Large-scale implementation of pooled RNA extraction and RT-PCR for SARS-CoV-2 detection

Sample pooling strategies for SARS-CoV-2 detection

Test Groups, Not Individuals: A Review of the Pooling Approaches for SARS-CoV-2 Diagnosis

The mathematical strategy that could transform coronavirus testing

Pooling Samples to Increase SARS-CoV-2 Testing

Simulation of pooled-sample analysis strategies for COVID-19 mass testing

The Right Kind of Pooled Testing for the Novel Coronavirus: First, Do No Harm

Modelling pool testing for SARS-CoV-2: addressing heterogeneity in populations

Optimally pooled viral testing

Boosting test-efficiency by pooled testing for SARS-CoV-2-Formula for optimal pool size

Increasing SARS-CoV-2 RT-qPCR testing capacity by sample pooling

Pooling of Upper Respiratory Specimens Using a SARS-CoV-2 Realtime RT-PCR Assay Authorized for Emergency Use in Low-Prevalence Populations for High-Throughput Testing

Pooled Testing for Surveillance of SARS-CoV-2 in Asymptomatic Individuals

Evaluation of sample pooling for SARS-CoV-2 RNA detection in nasopharyngeal swabs and salivas on the Roche Cobas 6800

Pooling of Nasopharyngeal Swab Samples To Overcome a Global Shortage of Real-Time Reverse Transcription-PCR COVID-19 Test Kits

Saliva sample pooling for the detection of SARS-CoV-2

Evaluation of COVID-19 RT-qPCR Test in Multi sample Pools

Pooling of coronavirus tests under unknown prevalence

Effectiveness of Sample Pooling Strategies for SARS-CoV-2 Mass Screening by RT-PCR: A Scoping Review

Lessons from applied large-scale pooling of 133,816 SARS-CoV-2 RT-PCR tests

Evaluation of Commercial qPCR Kits for Detection of SARS-CoV-2 in Pooled Samples

Culture-Based Virus Isolation To Evaluate Potential Infectivity of Clinical Specimens Tested for COVID-19

Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards

Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19

Increased SARS-CoV-2 Testing Capacity with Pooled Saliva Samples

Performance of Nucleic Acid Amplification Tests for Detection of Severe Acute Respiratory Syndrome Coronavirus 2 in Prospectively Pooled Specimens

Assessment of Specimen Pooling to Conserve SARS CoV-2 Testing Resources

Assessment of Sample Pooling for Clinical SARS-CoV-2 Testing

Evaluation of pooling of samples for testing SARS-CoV-2 for mass screening of COVID-19

A Data-Driven Rationale for High-Throughput SARS-CoV-2 Mass Screening Programs

COVID-19) update: FDA issues first emergency authorization for sample pooling in diagnostic testing

Unveiling the silent threat among us: leveraging health information technology in the search for asymptomatic COVID 19 healthcare workers

Impact of delays on effectiveness of contact tracing strategies for COVID-19: a modelling study

Rapid Scaling Up of Covid-19 Diagnostic Testing in the United States -The NIH RADx Initiative

Review of analytical performance of COVID-19 detection methods

Testing at scale during the COVID-19 pandemic

COVID-19 diagnostics in context

An alternative workflow for molecular detection of SARS-CoV-2 -escape from the NA extraction kit-shortage

Evaluation of two automated low-cost RNA extraction protocols for SARS-CoV-2 detection

SalivaDirect: A simplified and flexible platform to enhance SARS-CoV-2 testing capacity

A two minute liquid based sample preparation for rapid SARS-CoV2 real-time PCR screening: A multicentre evaluation

Versatile and flexible microfluidic qPCR test for highthroughput SARS-CoV-2 and cellular response detection in nasopharyngeal swab samples

A simple, safe and sensitive method for SARS-CoV-2 inactivation and RNA extraction for RT-qPCR

A direct RT-qPCR approach to test large numbers of individuals for SARS-CoV-2

Efficacy of a novel SARS-CoV-2 detection kit without RNA extraction and purification

Optimization of primer sets and detection protocols for SARS-CoV-2 of coronavirus disease 2019 (COVID-19) using PCR and real-time PCR

Multiplexing primer/probe sets for detection of SARS-CoV-2 by qRT-PCR

SARS-CoV-2-Positive Sputum and Feces After Conversion of Pharyngeal Samples in Patients With COVID-19

Diagnostics for SARS-CoV-2 infections

CRISPR-Cas12-based detection of SARS-CoV-2

Detection of SARS-CoV-2 with SHERLOCK One-Pot Testing

Clinical validation of a Cas13-based assay for the detection of SARS-CoV-2 RNA

Massively multiplexed nucleic acid detection with Cas13

Optimized and scalable synthesis of magnetic nanoparticles for RNA extraction in response to developing countries' needs in the detection and control of SARS-CoV-2

Selective Naked-Eye Detection of SARS-CoV-2 Mediated by N Gene Targeted Antisense Oligonucleotide Capped Plasmonic Nanoparticles

Dual-Functional Plasmonic Photothermal Biosensors for Highly Accurate Severe Acute Respiratory Syndrome Coronavirus 2 Detection

Rapid, Ultrasensitive, and Quantitative Detection of SARS-CoV-2 Using Antisense Oligonucleotides Directed Electrochemical Biosensor Chip

Loop-Mediated Isothermal Amplification (LAMP): A Rapid, Sensitive, Specific, and Cost-Effective Point-of-Care Test for Coronaviruses in the Context of COVID-19 Pandemic

Reverse Transcription Loop-Mediated Isothermal Amplification Assay for Ultrasensitive Detection of SARS-CoV-2 in Saliva and Viral Transport Medium Clinical Samples

Multiplex reverse transcription loop-mediated isothermal amplification combined with nanoparticle-based lateral flow biosensor for the diagnosis of COVID-19

Rapid implementation of SARS-CoV-2 sequencing to investigate cases of health-care associated COVID-19: a prospective genomic surveillance study

An integrated national scale SARS-CoV-2 genomic surveillance network

Data, disease and diplomacy: GISAID's innovative contribution to global health

SARS-CoV-2 variants, spike mutations and immune escape

A multiplexed, next generation sequencing platform for high-throughput detection of SARS-CoV-2

Rapid High-Throughput Whole-Genome Sequencing of SARS-CoV-2 by Using One-Step Reverse Transcription-PCR Amplification with an Integrated Microfluidic System and Next-Generation Sequencing

Wastewater surveillance for population-wide Covid-19: The present and future

Notes from the Field: Early Evidence of the SARS-CoV-2 B.1.1.529 (Omicron) Variant in Community Wastewater -United States

Surveillance of SARS-CoV-2 lineage B.1.1.7 in Slovakia using a novel, multiplexed RT-qPCR assay

Mutation-Specific SARS-CoV-2 PCR Screen: Rapid and Accurate Detection of Variants of Concern and the Identification of a Newly Emerging Variant with Spike L452R Mutation

Genotyping Reverse Transcriptase PCR for Population-Level Variant Screening and Epidemiologic Surveillance

Considerations for diagnostic COVID-19 tests

Vitro Diagnostics EUAs -Molecular Diagnostic Tests for SARS-CoV-2

Alarming COVID variants show vital role of genomic surveillance

Analytical and Clinical Comparison of Three Nucleic Acid Amplification Tests for SARS-CoV-2 Detection

Comparison of Four Molecular In Vitro Diagnostic Assays for the Detection of SARS-CoV-2 in Nasopharyngeal Specimens

Comparison of Two High-Throughput Reverse Transcription-PCR Systems for the Detection of Severe Acute Respiratory Syndrome Coronavirus 2

Validation and verification of the Abbott RealTime SARS-CoV-2 assay analytical and clinical performance

Real-life head-to-head comparison of performance of two high-throughput automated assays for detection of SARS-CoV-2 RNA in nasopharyngeal swabs: the Alinity m SARS-CoV-2 and cobas 6800 SARS-CoV-2 assays

Validation of a modified CDC assay and performance comparison with the NeuMoDx and DiaSorin(R) automated assays for rapid detection of SARS-CoV-2 in respiratory specimens

Multicenter evaluation of the NeuMoDx SARS-CoV-2 Test